Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
Sara Elena Rebuzzi,Alessio Signori,Giuseppe Luigi Banna,Marco Maruzzo,Ugo De Giorgi,Paolo Pedrazzoli,Andrea Sbrana,Paolo Andrea Zucali,Cristina Masini,Emanuele Naglieri,Giuseppe Procopio,Sara Merler,Laura Tomasello,Lucia Fratino,Cinzia Baldessari,Riccardo Ricotta,Stefano Panni,Veronica Mollica,Mariella Sorarù,Matteo Santoni,Alessio Cortellini,Veronica Prati,Hector Soto Parra,Marco Stellato,Francesco Atzori,Sandro Pignata,Carlo Messina,Marco Messina,Franco Morelli,Giuseppe Prati,Franco Nolè,Francesca Vignani,Alessia Cavo,Giandomenico Roviello,Francesco Pierantoni,Chiara Casadei,Melissa Bersanelli,Silvia Chiellino,Federico Paolieri,Matteo Perrino,Matteo Brunelli,Roberto Iacovelli,Camillo Porta,Sebastiano Buti,Giuseppe Fornarini +44 more
Reads0
Chats0
TLDR
The Meet-URO score allowed for the accurate stratification of pretreated mRCC patients receiving nivolumab and is easily applicable for clinical practice at no additional cost.Abstract:
Background:Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, the identification of prognostic biomark...read more
Citations
More filters
Journal ArticleDOI
The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy
Ziting Qu,Qianling Wang,Hui Yun Wang,Yang Jiao,Min Li,Wei Wei,Yuyang Lei,Zhicheng Zhao,Tengteng Zhang,Yiyin Zhang,Kangsheng Gu +10 more
TL;DR: NLR, PLR, MLR, dNLR and SII can reflect the short-term efficacy of immunotherapy in patients who underwent anti-PD-1 therapy with AGC and are an independent prognostic factor for OS in AGC patients receiving second-line or posterior immunotherapy.
Journal ArticleDOI
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
Jinbo Chen,Zhenyu Ou,Haige Chen,Zheng Liu,Minfeng Chen,Ruiyun Zhang,Anze Yu,Rui Cao,Enchong Zhang,Xi Guo,Bo Peng,D. Deng,Chun-ying Cheng,Jinhui Liu,Huihuang Li,Yihua Zou,Ruoping Deng,Gang Qin,Wenze Li,Lue Wang,Tao Chen,Xiaming Pei,Guanghui Gong,Jiansheng Tang,Belaydi Othmane,Zhi-gao Cai,Chunyu Zhang,Zhi Bo Liu,Xiongbing Zu +28 more
TL;DR: In this paper , a multi-center, real-world cohort study that enrolls 253 patients treated with neoadjuvant treatments (combination therapy: 98, chemotherapy: 107, and immunotherapy: 48) from 15 tertiary hospitals was performed.
Journal ArticleDOI
Complete blood count-derived inflammatory markers and survival in patients with localized renal cell cancer treated with partial or radical nephrectomy: a retrospective single-tertiary-center study.
Łukasz Zapała,Aleksander Ślusarczyk,Karolina Garbas,Łukasz Mielczarek,Cezary Ślusarczyk,Piotr Zapała,Andrzej Wróbel,Piotr Radziszewski +7 more
TL;DR: For the first time, the prognostic value of neutrophil-to-erythrocyte ratio is shown, which constitutes an independent risk factor of overall survival and is shown to be prognostic for overall survival.
Journal ArticleDOI
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.
Giuseppe Luigi Banna,Ornella Cantale,Sethupathi R. Muthuramalingam,Judith Cave,Charles Comins,Alessio Cortellini,Alfredo Addeo,Alessio Signori,H Mckenzie,C. Escriu,Gloria Barone,Sam Chan,Alexander Hicks,H. Bainbridge,David J. Pinato,Christian H. Ottensmeier,Fabio Gomes +16 more
TL;DR: In this paper , the authors collected data from patients in six United Kingdom and one Swiss oncology centres with first-line pembrolizumab plus platinum-based chemotherapy.
Journal ArticleDOI
Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence.
Sara Elena Rebuzzi,Giuseppe Luigi Banna,Veronica Murianni,Alessandra Damassi,Emilio Francesco Giunta,Filippo Fraggetta,Ugo De Giorgi,Richard Cathomas,Pasquale Rescigno,Matteo Brunelli,Giuseppe Fornarini +10 more
TL;DR: In this paper, the authors describe the prognostic and predictive role, and clinical readiness, of clinical and tumour factors, including new molecular classes, tumour mutational burden, mutational signatures, circulating tumour DNA, programmed death-ligand 1, inflammatory indices and clinical characteristics for patients with urothelial cancer treated with ICIs.
References
More filters
Journal Article
R: A language and environment for statistical computing.
TL;DR: Copyright (©) 1999–2012 R Foundation for Statistical Computing; permission is granted to make and distribute verbatim copies of this manual provided the copyright notice and permission notice are preserved on all copies.
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Hallmarks of cancer: the next generation.
TL;DR: Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Marco Gerlinger,Andrew Rowan,Stuart Horswell,James Larkin,David Endesfelder,Eva Grönroos,Pierre Martinez,Nicholas Matthews,Aengus Stewart,Patrick S. Tarpey,Ignacio Varela,Benjamin Phillimore,Sharmin Begum,Neil Q. McDonald,Adam Butler,David T. Jones,Keiran Raine,Calli Latimer,Claudio R. Santos,Mahrokh Nohadani,Aron Charles Eklund,Bradley Spencer-Dene,Graham Clark,Lisa Pickering,Gordon Stamp,Martin Gore,Zoltan Szallasi,Zoltan Szallasi,Julian Downward,P. Andrew Futreal,Charles Swanton +30 more
TL;DR: Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development.